AstraZeneca PLCAZNNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank64
3Y CAGR+161.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+161.5%/yr
vs -45.6%/yr prior
Acceleration
+207.1pp
Accelerating
Percentile
P64
Within normal range
vs 3Y Ago
17.9x
Strong expansion
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 4.78% |
| 2024 | 24.22% |
| 2023 | 12.02% |
| 2022 | 0.27% |
| 2021 | 62.51% |
| 2020 | -1.12% |
| 2019 | 2.14% |
| 2018 | 3.04% |
| 2017 | -2.26% |
| 2016 | -1.78% |